Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
April 17, 2024 16:05 ET
|
Serina Therapeutics, Inc.
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE...
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
March 26, 2024 17:04 ET
|
Serina Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the...
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
March 22, 2024 17:27 ET
|
AgeX Therapeutics, Inc.
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported...
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
November 17, 2023 08:00 ET
|
Serina Therapeutics, Inc.
Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a...